• Jiangsu Hengrui Medicine entered global strategic collaboration and licensing deal with Bristol Myers Squibb on May 12, 2026, covering 13 preclinical programs across oncology, hematology, immunology.
• BMS to pay up to USD 950 million in upfront-related payments, including USD 600 million upfront, USD 175 million first anniversary payment, USD 175 million conditional 2028 anniversary payment.
• Potential total value up to about USD 15.2 billion tied to option exercises and development, regulatory, commercialization milestones; Hengrui also eligible for tiered royalties on net sales outside mainland China, Hong Kong, Macau.
• BMS receives exclusive rights outside mainland China, Hong Kong, Macau for Hengrui-originated programs and jointly developed programs; Hengrui receives exclusive rights in those territories for BMS-originated programs.
• Deal subject to U.S. Hart-Scott-Rodino clearance and customary closing conditions; closing expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260512-12155763), on May 12, 2026, and is solely responsible for the information contained therein.